Journal article
The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation
Abstract
BACKGROUND: Infants born at 33 through 35 completed weeks of gestation (33-35GA) are at risk for severe respiratory syncytial virus (RSV) infection, and palivizumab prophylaxis lowers hospitalizations for RSV infection by as much as 80%. The 33-35GA cohort comprises 3-5% of annual births; thus expert panels recommend limiting prophylaxis to situations in which frequency or health care impact of RSV infection is high. This study sought to …
Authors
Law BJ; Langley JM; Allen U; Paes B; Lee DSC; Mitchell I; Sampalis J; Walti H; Robinson J; O’Brien K
Journal
The Pediatric Infectious Disease Journal, Vol. 23, No. 9, pp. 806–814
Publisher
Wolters Kluwer
Publication Date
September 2004
DOI
10.1097/01.inf.0000137568.71589.bd
ISSN
0891-3668
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCanadaCohort StudiesFemaleGestational AgeHospitalizationHumansInfant, NewbornInfant, PrematureLogistic ModelsMaleMultivariate AnalysisPalivizumabPredictive Value of TestsPregnancyPrevalenceProbabilityRespiratory Syncytial Virus InfectionsRisk AssessmentSeverity of Illness IndexSex FactorsSurvival RateTreatment Outcome